2025-01-06
Great Bay Bio self-developed AI-enabled cell culture media, AlfaMedX (NF3370+DF2025), leverages cutting-edge technologies, including AI, to analyze and predict large volumes of experimental data. This approach optimizes the composition and usage conditions of the media, significantly improving protein expression performance.
Since its launch, AlfaMedX (NF3370+DF2025) has received trial data from several of our customers. Comparative studies with 17 commercial media on cell line cultures for fusion proteins, mAbs, and BsAbs have demonstrated its significant advantages in protein yield and versatility. Trial data from 20 different cell lines showed that, compared to commercial media, GBB’s AlfaMedX (NF3370+DF2025) achieved expression levels at or above 90% of the top-performing commercial media in 9 cell lines, with its expression ranking consistently within the top 3.
Detailed
trial data are shown below:
Accepted for Both Oral Presentation and Poster! Two Great Bay Bio Technology Advancements Enabling Antibody R&D for Obesity Targets Selected for Obesity Week® 2026
2026-08-12
AlfaCell Platform Enables Client’s Out-Licensed Pipeline to Successfully Enter Phase II Clinical Trials, Advancing Novel Drugs and Biosimilars in Parallel
2026-08-07
Platform Case | AI Tackles Challenging GPCR Drug Target in 8 Months! AlfaBodY Platform of Great Bay Bio Generates Long-Acting Non-Rebound Weight-Loss Antibody; Research Findings Published
2026-07-17
